Diabetic Retinopathy: A Concise Review
Keywords:
Diabetic Retinopathy, Laser Treatment, VitrectomyAbstract
Diabetic retinopathy is most important diabetic complication and remains the primary cause of avoidable blindness in working-aged persons. As the global prevalence of diabetes mellitus continues to increase, diabetic retinopathy remains a principal cause of vision loss in several developed countries. Most favorable control of blood pressure, blood glucose, and possibly blood lipids remains the foundation for decrease of risk of retinopathy development. Novel approaches for DR treatment are intraocular steroid injection and anti-vascular endothelial growth-factor (VEGF) agents, are less damaging to the retina than are older treatments. This article will summarize key detection and management approaches for the complications of diabetes with special prominence on retinopathic complications.
Downloads
References
Abcouwer SF, Gardner TW. Diabetic retinopathy: loss of neuroretinal adaptation to the diabetic metabolic environment. Annals of the New York Academy of Sciences. 2014; 1311: 174–190.
Ola MS, Nawaz MI, Siddiquei MM, Al-Amro S, Abu El-Asrar AM. Recent advances in understanding the biochemical and molecular mechanism of diabetic retinopathy. Journal of Diabetes and Its Complications. 2012; 26(1): 56– 64.
Qian HH, Ripps. Neurovascular interaction and the pathophysiology of diabetic retinopathy. Experimental Diabetes Research.2011; 2011: 1-11.
Tarr JM, Kaul KM, Chopra EM, Kohner, Chibber R. Pathophysiology of diabetic retinopathy. ISRN Oph-thalmology. 2013; 2013: 1-13.
Antonetti DA, Barber AJ, Bronson SK. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease. Diabetes.2006; 55(9): 2401–2411,
Hernandez C, Simo R, Neuro-protection in diabetic retinopathy. Current Diabetes Reports, 2012; 12(4): 329– 337,
Jindal V. Neurodegeneration as a primary change and role of neuroprotection in diabetic retinopathy. Molecular Neurobiology. 2015; 51(3): 878–884,.
Zhang X, Wang N, Barile GR, Bao S, Gillies M. Diabetic retinopathy: neuron protection as a therapeutic target. International Journal of Biochemistry and Cell Biology. 2013; 45(7): 1525–1529,
Simo R, Hernandez C. Novel approaches for treating diabetic retinopathy based on recent pathogenic evidence. Progress in Retinal and Eye Research. 2015; 48: 160–180.
Diabetic Retinopathy Study Research Group. Preliminary report on effects of photocoagulation therapy. Am. J. Ophthalmol. 1976; 81: 383–396.
Patz A, Smith RE. The ETDRS and diabetes 2000. Ophthalmology. 1991; 98: 730–740.
Abdulrahma A. Alghadyan M.D. Diabetic retinopathy – An update. Saudi Journal of Ophthalmology. 2011, 25, 99-111
Curtis TM, Gardiner TA, Stitt AW. Microvascular lesions of diabetic retinopathy: clues towards under-standing pathogenesis? Eye.2009; 23: 1496–1508.
Antonetti DA, Barber AJ, Bronson SK. Diabetic retinopathy: seeing beyond glucose-induced microvascular disease.Diabetes.2006; 55: 2401–11.
Ciulla TA, Amador AG, Zinman B. Diabetic retinopathy and diabetic macular edema: pathophysiology, screening, and novel therapies. Diabetes Care.2003; 26: 2653–64.
New treatments for diabetic retinopathyDas1,2, S. Stroud1, A. Mehta1 & S. Rangasamy3 Diabetes, Obesity and Metabolism.17: 219–230, 2015.
Early photocoagulation for diabetic retinopathy. ETDRS report number 9. Early Treatment Diabetic Retinopathy Study Research Group. Ophthalmology. 1991; 98: 766-785.
Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Two-year results ofa randomized trial. Diabetic Retinopathy Vitrectomy Study report 2. The Diabetic Retinopathy Vitrectomy Study Research Group. Arch.Ophthalmol. 1985; 103: 1644-1652.
Early vitrectomy for severe vitreous hemorrhage in diabetic retinopathy. Four-year results of a random-ized trial: Diabetic Retinopathy Vitrectomy Study Report 5 Arch Ophthalmol.1990; 108: 958-964.
Smiddy WE, Flynn HW. Vitrectomy in the management of diabetic retinopathy. Surv. Ophthalmol. 1999; 43: 491-507.
Pendergast SD, Hassan TS, William GA. Vitrectomy for diffuse diabetic macular edemaassociated with a taut premacular posterior hyaloid. Am J Ophthalmol. 2000; 130: 178-186.
Kaiser PK, Riemann CD, Sears JE, Lewis H. Macular traction detachment and diabetic macular edema associated with posterior hyaloidal traction. Am J Ophthalmol. 2001;131:44-
Wilson A, Baker R, Thompson J, Grimshaw G. Coverage in screening for diabetic retinopathy according to screening provision: results from a national survey in England and Wales. Diabet. Med. 2004; 21: 271-278.
Sangha SS. Severe diabetic retinopathy after cataract surgery [letter]. Am. J. Ophthalmol. 1994; 118: 681-682.
Mittra RA, Borrillo JL, Dev S, Mieler WF, Koenig SB. Retinopathy progression and visual
Outcomes after phacoemulsification in patients with diabetes mellitus. Arch Ophthalmol. 2000; 118: 912-917.
Dowler JG, Hykin PG, Hamilton AM. Phacoemulsification versus extracapsular cataract
extraction in patients with diabetes. Ophthalmology. 2000; 107: 457-462.
Published
How to Cite
Issue
Section
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Copyright © Author(s) retain the copyright of this article.
